新型免疫抑制剂霉酚酸酯治疗狼疮性肾炎

目的观察新型免疫抑制剂霉酚酸酯(M.MF)治疗狼疮性肾炎的临床疗效和安全性。方法经肾活检证实的20例狼疮性肾炎,给予糖皮质激素联合MMF治疗。MMF初始剂量1.0～1.5g/d,治疗时间321个月,平均(10.9±6.2)个月。结果MMF治疗后24h尿蛋白定量从治疗前的平均5.55g下降至1.54g;d清白蛋白治疗前平均26.87g升至39g;6/8例肾功能不全患者3个月内Scr恢复正常;d清自身抗体产生明显减少,补体上升,其中ANA转阴率3个月达63％,6个月达81％;抗ds-DNA由治疗前23.77IU／ml下降至9.19IU／ml;2例重复活检,肾小球活动性病变明显减轻。MMF治疗的不良反应较少,偶有白细胞减少、感染、带状疱疹等。结论MMF对于各型狼疮性肾炎,尤其是Ⅳ型重症狼疮,经传统治疗无效者均有较好疗效,且长期应用不良反应少。     

乙型肝炎病毒相关肾炎临床与病毒血清学特点关联研究

目的 研究乙型肝炎病毒（HBV）感染与肾小球肾炎的关系,探讨HBV复制在HBV相关肾炎发病中的作用。方法 对338例经肾穿刺证实的肾炎患者的临床病理和病毒血清学特点进行分析。结果 HBV相关肾炎占肾炎总数的5．3％。在血HBsAg( )的肾炎患者中,HBV相关肾炎发病与HBeAg相关（P＜0．05）,与血清HBV DNA含量（bDNA)显著相关（P＜0．01）。分支链DNA（bDNA)阳性率明显高于HBeAg阳性率（P＜0．05）。结论 bDNA是反映HBV复制的最佳指标。HBV相关肾炎与体内HBV复制程度密切相关,HBV在体内大量复制,可能通过循环中的病毒抗原沉积于肾脏和肾脏中该抗原原位表达而致病。     

Investigating the effects of walnut ointment on non-healing burn wounds

Effective treatments for non-healing burn wounds are an unmet need for 95% of burn sufferers. Approaches currently available to treat non-healing burn wounds are not satisfactory due to undesirable side-effects or expense. The anti-oxidation and antibacterial activities of walnuts are recommended for treating chronic diseases. Walnut ointment has been developed and successfully applied to treat non-healing burn wounds in our hospital for decades. We report herein a detailed retrospective case review examining patients’ response to the walnut ointment. The walnut ointment has shortened healing time of non-healing burn wounds and improved clinical outcomes. In order to investigate the mechanism of action, walnut ointment has been applied on wounds of porcine full-thickness burn wound models. Histological and immunohistochemical analysis indicated our walnut ointment supports wound healing through promoting keratinocyte proliferation and differentiation. Taken together, we recommend the walnut ointment offers an effective and economical treatment for patients presenting with non-healing burn wounds.     

熟地黄药效物质基础研究进展

熟地黄为玄参科植物地黄Rehmannia glutinosa新鲜或干燥块根的炮制加工品,具有补血滋阴、益精填髓等功效。熟地黄是中药“滋阴”作用最具代表的药味之一,也被称之为“至阴之药”。熟地黄配伍相关经典方剂被广泛应用于治疗肝肾阴虚导致的各种临床疾病,包括糖尿病相关疾病、神经系统疾病、骨关节炎相关疾病、妇科相关疾病等。基于近年来发表的文献,对熟地黄化学成分、活性成分的药理作用、方剂配伍条件下的药效物质的基础研究进展进行综述,以期为熟地黄的深入研究提供参考。     

基于HS-GC-IMS技术分析六神曲炮制前后（炒、焦）挥发性物质的变化

目的 分析六神曲Massa Medicata Fermentata炮制前后（炒、焦）的挥发性有机物特征及其变化规律。方法 采用顶空-气相色谱-离子迁移质谱（headspace-gas chromatography-ion migration mass spectrometry,HS-GC-IMS）测定六神曲生品、炒品和焦品的挥发性有机物,构建HS-GC-IMS指纹图谱,采用VOCal软件对检测到的成分进行定性和定量分析,运用主成分分析（principal component analysis,PCA）、偏最小二乘-判别分析（partial least squares-discriminant analysis,PLS-DA）、t检验等对样品进行差异性分析。结果 基于HS-GC-IMS技术从六神曲生品、炒品和焦品中共获得了80种挥发性有机物,定性鉴别出60种;构建了六神曲生品、炒品和焦品的HS-GC-IMS指纹图谱,通过PCA、PLS-DA、t检验等分析方法可将三者进行区分,己醛-D(hexanal-D)、乙醇（ethanol）2种物质可作为六神曲生品的特征性成分;丁醛（butanal）...     

五味子中1个新的联苯环辛烯类木脂素

目的 研究中药五味子Schisandra chinensis的木脂素类化学成分。方法 采用硅胶柱色谱、中压反相柱色谱、半制备和制备液相对五味子中富含木脂素类成分的石油醚萃取部位进行分离、纯化,通过波谱数据鉴定化合物的结构。结果 从五味子中分离得到了26个化合物,分别鉴定为绿叶五味子素B(1)、sphaerandrin A(2)、sieverlignan E(3)、arisanschinin G(4)、widdaranalF(5)、戈米辛A(6)、戈米辛B(7)、戈米辛D(8)、戈米辛G(9)、(-)-戈米辛K1(10)、(+)-戈米辛K2(11)、(-)-戈米辛L₁(12)、(+)-戈米辛M1(13)、戈米辛N(14)、当归酰戈米辛H(15)、当归酰戈米辛O(16)、当归酰戈米辛Q(17)、苯甲酰戈米辛Q(18)、五味子醇甲(19)、五味子甲素(20)、五味子乙素(21)、五味子丙素(22)、五味子酯丙(23)、neglschisandrin E(24)、7(18)-dehydroschisandro A(25)、安五脂素(26),其中24个为联苯环辛烯类木脂素(...     

不同双膦酸盐类药物抑制破骨细胞特征曲线的意义

目的比较双膦酸盐类药物唑来膦酸、伊班膦酸和帕米膦酸对体外培育破骨细胞的具体抑制作用,绘制特征性曲线并指导临床治疗。方法通过体外培育小鼠骨髓细胞,分化获得破骨细胞并将其分为唑来膦酸组、伊班膦酸组、帕米膦酸组、对照组。其中,唑来膦酸组培养液中加入唑来膦酸,药物的阶梯浓度为:10-3、10-2、10-1、1、10、102、103μmol/L。同时,伊班膦酸组与帕米膦酸组加入相应药物的阶梯浓度相同,对照组加入磷酸盐缓冲液。观察双膦酸盐类药物对破骨细胞形成、迁移、粘附、骨破坏的抑制作用特征并进行比较,绘制特征性曲线。结果随着药物浓度逐级增大,多核细胞数量随浓度增加而减少。唑来膦酸、伊班膦酸和帕米膦酸的最低有效抑制浓度分别为1、10、102μmol/L。三者50%有效浓度分别为0.66、5.58、51.9μmol/L。结论临床治疗骨质疏松症时建议参考破骨细胞抑制特征曲线,为唑来膦酸、伊班膦酸和帕米膦酸的静脉应用提供科学依据。     

Status,Sources and Potential Risk of Polycyclic Aromatic Hydrocarbons in Soils from Hexi Corridor in Northwest China

Bulletin of Environmental Contamination and Toxicology - The Hexi Corridor is the main commodity grain base in northwest China and plays a special role in ensuring food security in northwest China....     

A head-to-head comparison of measurement properties of the EQ-5D-3L and EQ-5D-5L in acute myeloid leukemia patients

Quality of Life Research - This study aimed to compare the measurement properties of EQ-5D-3L(3L) and EQ-5D-5L(5L) in patients with acute myeloid leukemia (AML) in China. We consecutively recruited...     

Understanding the financial impact of a diagnosis of young onset dementia on individuals and families in the United Kingdom: Results of an online survey

Although literature on postdiagnostic support for people affected by young onset dementia acknowledges financial concerns, this topic has remained underresearched. The aim of this study was to explore the financial impact of a diagnosis of young onset dementia on individuals and families. An online survey, comprising binary yes/no, multiple-response and open-ended questions, was codesigned with people living with young onset dementia. The survey was promoted via networks and online platforms. Data were collected from August to October 2019. Survey respondents across the United Kingdom (n = 55) who had received a diagnosis of young onset dementia were aged between 45 and 64, were at different stages of dementia and had been diagnosed with thirteen different types of dementia. Of the 55 respondents, 71% (n = 39) had received assistance from family members when completing the survey. The main financial impact of a diagnosis of young onset dementia resulted from premature loss of income and reduced and often deferred pension entitlements. In some cases, care-costs became unaffordable. Lack of clarity of processes and procedures around needs assessments, carers' assessments and financial assessments by different organisations resulted in some families having to ask for legal advice and, in some cases, involved lengthy appeal processes. Future research needs to involve Adult Social Care and Third Sector organisations to help codesign and test financial management interventions to support people affected by this progressive health condition.